#56426 PRAME (E7I1B) Rabbit mAb
IHC-P: 抗体希釈液 / 抗原賦活化
|PRAME (E7I1B) Rabbit mAb recognizes endogenous levels of total PRAME protein. Non-specific non-nuclear staining was observed in smooth muscle.|
|Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Gly163 of human PRAME protein.|
ホモロジー (相同性) 検索をご希望の場合 >>>
Western blot analysis of various cell lines using PRAME (E7I1B) Rabbit mAb (upper) and β-Actin (D6A8) Rabbit mAb #8457 (lower). As expected, A172 cells show lower expression of PRAME.
Immunoprecipitation of PRAME protein from K562 cell extracts. Lane 1 is 10% input, lane 2 is Rabbit (DA1E) mAb IgG XP® Isotype Control #3900, and lane 3 is PRAME (E7I1B) Rabbit mAb. Western blot analysis was performed using PRAME (E7I1B) Rabbit mAb. Mouse Anti-rabbit IgG (Conformation Specific) (L27A9) mAb (HRP Conjugate) #5127 was used for detection to avoid cross reactivity with IgG.
Immunohistochemical analysis of paraffin-embedded human lung carcinoma using PRAME (E7I1B) Rabbit mAb.
Immunohistochemical analysis of paraffin-embedded human ovarian carcinoma using PRAME (E7I1B) Rabbit mAb.
Immunohistochemical analysis of paraffin-embedded K-562 cell pellet (left, high-expressing) or A172 cell pellet (right, low-expressing) using PRAME (E7I1B) Rabbit mAb.
Immunohistochemical analysis of paraffin-embedded human testis using PRAME (E7I1B) Rabbit mAb.
Cancer/testis antigens (CTAs) are a family of more than 100 proteins whose normal expression is largely restricted to immune privileged germ cells of the testis, ovary, and trophoblast cells of the placenta. Although most normal somatic tissues are void of CTA expression, due to epigenetic silencing of gene expression, their expression is upregulated in a wide variety of human solid and liquid tumors (1,2). As such, CTAs have garnered much attention as attractive targets for a variety of immunotherapy-based approaches to selectively attack tumors (3).
PRAME (preferentially expressed antigen in melanoma) is a cancer/testis antigen not normally expressed in any tissues except testis, but is upregulated in tumors. PRAME is expressed in melanoma cells and is recognized by cytolytic T-cells (4). It is also upregulated in other diseases, such as synovial sarcoma (5), NSCLC (6), and breast cancer, where it is thought to contribute to tumorigenesis and metastasis (7). PRAME is also highly expressed in liquid tumors such as AML (8) and can be predictive of clinical outcome in some circumstances (9). PRAME and other cancer/testis antigens are currently being pursued as novel immunotherapy targets and diagnostic biomarkers (10).
- Caballero, O.L. and Chen, Y.T. (2009) Cancer Sci 100, 2014-21.
- De Smet, C. et al. (1999) Mol Cell Biol 19, 7327-35.
- Gjerstorff, M.F. et al. (2015) Oncotarget 6, 15772-87.
- Ikeda, H. et al. (1997) Immunity 6, 199-208.
- Iura, K. et al. (2017) Hum Pathol 61, 130-139.
- Gunn, R.B. and Fröhlich, O. (1989) Methods Enzymol 173, 54-80.
- Sun, Z. et al. (2016) Gene 594, 160-164.
- Qin, Y.Z. et al. (2017) Oncol Lett 13, 2823-2830.
- Oehler, V.G. et al. (2009) Blood 114, 3299-308.
- Salmaninejad, A. et al. (2016) Immunol Invest 45, 619-40.
Tween is a registered trademark of ICI Americas, Inc.
SignalStain is a trademark of Cell Signaling Technology, Inc.
XP is a registered trademark of Cell Signaling Technology, Inc.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.